Serina Therapeutics, Inc. (SER)

NYSEAMERICAN: SER · USD

$1.61

-0.06 (-3.6%)· Recorded snapshot

Market cap	40.9M
Net income (ttm)	-23.9M
EPS (ttm)	-$1.93
Shares out	25.4M
Volume	27,379
Beta	0.16

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -23.9M
EPS (ttm): -$1.93
Market cap: 40.9M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	보유

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROE-207.9

P25 -113.8P50 -46.5P75 -0.9

ROIC-131

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All SER indicators

Market & fundamental data

Available fields

170

Groups with data

Currency

USD

Showing 170 of 170 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001708599
Company name	Serina Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	81751A108
Earnings date	2026-11-12
Earnings time	bmo
Employees	16
Employees change	3
Employees growth	23.08%
Enterprise value	$21.6M
Exchange	NYSEAMERICAN
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2017
Industry	Biotechnology
IPO date	2018-11-29
Is primary listing	Yes
Is SPAC	No
ISIN number	US81751A1088
Last 10-K release date	2026-03-25
Last earnings date	2026-08-13
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$40.9M
Market cap category	Nano-Cap
Next earnings date	2026-11-12
Options	No
Price	$1.61
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	SER
U.S. state	Alabama
Website	https://serinatherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-120.18%
FCF / EV yield	-91.59%
FCF yield	-49.98%
P/B ratio	2.26x
Price / tangible book value	2.26x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-1.5M
ROA	-92.3%
ROCE	-116.37%
ROE	-207.94%
ROIC	-130.98%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	0
Net income growth years	0
Revenue growth	132.14%
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-66,000
Depreciation and amortization	$76,000
EBIT	$-25.7M
EBITDA	$-25.6M
EPS	$-1.93
FCF per share	$-0.83
Financing cash flow	$38.2M
Free cash flow	$-21.2M
Free cash flow minus SBC	$-25.3M
Gross profit	$-14.1M
Income taxes	$18,000
Investing cash flow	$-66,000
Net borrowing	$4.9M
Net cash flow	$17M
Net income	$-23.9M
Operating cash flow minus SBC	$-25.2M
Operating income	$-25.7M
Stock-based compensation	$4.1M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-3.31
Book value per share	$0.74
Debt / equity	0.2
Interest coverage	-43.06
Long-term assets	$784,000
Long-term liabilities	$3.3M
Net cash (debt)	$19.3M
Net cash / market cap	45.43%
Net cash growth	239.32%
Net debt / equity	-1.03
Piotroski F-Score	2
Property, plant and equipment	$759,000
Shareholders' equity	$18.7M
Tangible book value	$18.7M
Tangible book value per share	$0.74
Total assets	$25.8M
Total cash	$23M
Total debt	$3.8M
Total liabilities	$7.1M
WACC	5.71%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$25M
Current liabilities	$3.8M
Current ratio	6.65
Net working capital	$-1.2M
Quick ratio	6.12
Working capital	$21.3M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-30.5%
Dividend yield	0%
Shareholder yield	-30.5%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$2.07
1D price change	-3.59%
1M price change	-22.04%
1M total return	-22.04%
1W price change	-1.85%
1W total return	-1.85%
1Y price change	-67.86%
1Y return CAGR	-67.89%
1Y total return	-67.86%
20-day SMA	$1.82
200-day SMA	$2.10
3M price change	-22.41%
3M total return	-22.41%
50-day SMA	$2.18
50-day SMA vs 200-day SMA	50over200
52-week high	$5.09
52-week high date	2025-10-28
52-week low	$1.22
52-week low date	2026-03-18
6M price change	-9.48%
6M total return	-9.48%
All-time high	$19.93
All-time high date	2024-03-27
All-time low	$1.22
All-time low date	2026-03-18
Average true range (ATR)	$0.18
Average volume	41.2K
Beta (1Y)	1.37
Beta (2Y)	0.26
Beta (5Y)	0.16
Change from 52-week high	-68.37%
Change from 52-week low	31.97%
Change from all-time high	-91.82%
Change from all-time low	33.55%
Change from open	0%
Day's gap	-3.59%
Dollar volume	$44,080
High price	$1.61
Low price	$1.61
Monthly RSI	24.09
Open price	$1.61
Premarket change	-0.6%
Premarket close	$1.67
Premarket price	$1.66
Previous close	$1.67
Price vs 150-day SMA	-21.14%
Price vs 20-day SMA	-10.67%
Price vs 200-day SMA	-22.27%
Price vs 50-day SMA	-25.26%
Relative volume	0.66
RSI	34.33
Sharpe ratio	-0.28
Sortino ratio	-0.49
Volume	27.4K
Weekly RSI	38.87
YTD price change	-14.83%
YTD total return	-14.83%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	11.1M
Float percentage	43.89%
Shares change (QoQ)	36.01%
Shares change (YoY)	30.5%
Shares held by insiders	39.67%
Shares held by institutions	5.55%
Shares outstanding	25.4M
Short % of float	0.51%
Short % of shares	0.22%
Short ratio	0.6 days

Deeper analysis on SER

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this SER report

Is a complete SER research report available?

No complete published report is available for Serina Therapeutics, Inc. (SER) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Serina Therapeutics, Inc. (SER)

Price

Financial snapshot

Fair-value bridge

Latest news · SER

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All SER indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on SER

Frequently asked questions